

Anticandida activities of essential oil of *Salvia macrosiphon*, in a single form and comparison with fluconazole

Abstract

Aims: Candidiasis is the most opportunistic infection with a high rate of recurrent infection. *Salvia macrosiphon* has antibacterial effect, however, its' antifungal effect was not studied. This study aimed to investigate the chemical composition of essential oil from leaves of *Salvia macrosiphon* with its antifungal activity of it compared with fluconazole.

Materials & Methods: *Salvia macrosiphon* leaves, a native plant of Kogiluyeh and boyerahmad states, were collected from Zagros heights, and used in this study. Then, the essential oil of this plant was tested for antibacterial and antifungal properties and compared with fluconazole. The chemical composition of the essential oil was analyzed by GC/MS (Gas Chromatography Mass Spectrometry) and the antifungal activity of the plant essential oil was compared with fluconazole.

Findings: The results of GC-MS analysis proved the presence of at least 29 compounds in the essential oil of *Salvia macrosiphon*. Among these constitute, butyl benzoate (49.16%), n-hexyl benzoate (7%), and isopatenol (4.83%) were the main compound. The minimum inhibitory concentration (MIC) of the essential oil ($\mu\text{l/ml}$) of *Salvia macrosiphon* and fluconazole ($\mu\text{g/ml}$) were 0.44 and 0.7 for *Candida albicans*, 0.056 and 0.7 for *C. glabrata*, and 0.1 and 0.088 for *C. parapsilosis*, respectively. Also, statistical analysis demonstrated that there was a significant difference between the mean of fluconazole and essential oil in total *Candida* isolates ($p=0.001$, $p<0.05$).

Conclusion: Based on the results and other studies, the essential oil of *Salvia macrosiphon* can be used as a new drug or a source of antifungal compounds alone or as a supplement with industrial drugs. Also, our findings in this study showed stronger antifungal activity of plant essential oil compared to fluconazole.

Keywords

Salvia Macrosiphon
Essential Oils
Candida Albicans
Candida Glabrata
Candida Parapsilosis

Introduction

Candidiasis is the most opportunistic infection and causes a variety of clinical forms. This infection may be superficial (e.g., oral, nail), mucocutaneous (e.g. vaginal), or systemic (e.g. candidemia, candiduria) [1]. Different species of *Candida* have been introduced as agents of candidiasis such as *C. albicans*, *C. glabrata*, *C. tropicalis*, *C. krusei*, and *C. dubliniensis* [2]. Although *C. albicans* is the most common cause of the disease, the prevalence of non-*albicans* species is also increasing [3]. Even though common *C. albicans* infections are easily treatable, systemic infections, frequently of a nosocomial nature, have a high mortality rate. Therefore, early diagnosis and management of infection are necessary [4]. There are different classes of antifungal drugs and uses for various forms of candidiasis. These drugs included azole classes (eg., imidazole and triazole), echinocandin (eg., caspofungin), and polyene (eg., amphotericin B) [5]. Fluconazole is one of the triazole drugs and is widely used in mucocutaneous and systemic forms of candidiasis. In the past two decades, several genes and mutations that increase resistance to fluconazole in clinical isolates, primarily in *C. albicans*, have been elucidated [6].

The use of herbal plants and their products has been considered for a long time. Some properties such as ease of access, lack of side effects, and drug resistance have caused these compounds to always be used in the treatment of various diseases. The genus of *Salvia* belongs to the Lamiaceae family and possesses more than 100 species. Many countries have been introduced as the inhabitants of this genus [7]. Iran is also an endemic region of this genus and there are 61 flora species in this region [8]. Generally, *Salvia* species are used in foods, cosmetics, perfumery, and pharmaceutical industries. *Salvia macrosiphon* (*S. macrosiphon*) known as Maryam Goli Lolei or Marvak in Persian has been used in traditional medicine. This species is the most valuable type of the Lamiaceae family and has therapeutic effects. The habitat of this species is in Iran and Afghanistan and due to its essential oil and tannin, its leaves have a strengthening and tonic effect, in addition, they facilitate digestion, are diuretic, anticonvulsant, antipyretic, and reduce blood sugar. It is used externally to heal and disinfect wounds [9]. Some fractions of *S. macrosiphon* have been introduced as antibacterial agents. For instance, the antibacterial effects of the plant's n-hexane, chloroform, and ethyl acetate fractions on *Staphylococcus aureus* and *E. coli* were tested in one study, and the results showed good activity with MIC values ranging from 0.61 to 2.5mg/mL [10]. Today, the problem of resistance of *Candida* species to existing chemical drugs, as well as complications and high cost of chemical drugs, is observed, and there is a tendency to use medicinal plants as medicinal and antifungal compounds [11]. Therefore, this study aimed to investigate the chemical composition of essential oil from leaves of *Salvia macrosiphon* with its antifungal activity of it compared with fluconazole.

Material and Methods

Design and samples

This study was designed based on the clinical laboratory research method from 2021 to 2022. 56 *C. albicans* were collected from the patient's samples including vulvovaginal swabs, ear swabs, blood and urine specimens, were studied.

Plant material

The aerial parts of *S. macrosiphon* were collected and the identification process was done and approved in the Kerman Agriculture and Natural Resources Research and Education Center and the herbarium number was obtained (herbarium number: 17714). The aerial parts were crushed and dried at room temperature. 200 g of dried powder mixed with 1 L of distilled water and the essential oil hydrodistilled in a Clevenger apparatus according to the British method for 3h. Finally, the essential oil was preserved at 4°C in a dark condition until other steps.

Gas chromatography /Mass spectrometry

The GC/MS method was used to analyze the components of the essential oil of the *S. macrosiphon* fruit at Kashan University of Medical Sciences. Chromatography (Brand Agilent, model 6890; USA) and mass spectrometry were used for qualitative and quantitative measurements of compounds. At first, the temperature was set at 60°C, and then it was raised to 246°C at a rate of 3°C. The combination of gas chromatography and mass spectrometry characteristics is used to identify different substances present in a sample.

Antifungal susceptibility test

1- Preparation of *Candida* isolate

56 *C.albicans* (including 15 blood cultures, 40 vulvovaginitis, recurrent vulvovaginitis, and 1 otomycosis isolates), 12 *C.glabrata* (6 vulvovaginitis, 6 urine culture isolates), 12 *C.parapsilosis* (3 blood cultures, 9 otomycosis isolates) were studied. Candidal isolates were collected from the patient's samples (vulvovaginal swabs, ear swabs, and blood and urine specimens). Vaginal samples were taken from suspected patients with VVC that had been referred to gynecology and (obstetrics) private midwifery clinics in Yasuj, Iran from 2021 to 2022. Other samples including blood culture, urine, and ear swabs were referred to the medical school of Yasuj University of Medical Science and identified based on molecular methods. All *Candida* isolates were subculture on Sabouraud Dextrose Agar (Biolife; India) and incubated at 37°C. Then fresh isolates were used for other steps.

2- Determination of minimum inhibitory concentration (MIC)

An antifungal susceptibility test was carried out based on CLSI-M27-A3 guidelines [12]. Fungal suspensions were prepared by fresh colonies and distilled water and standardized using a spectrophotometer (Brand JENWAY, Model 6320D; China) in 530nm and 75-77 transmittance. For broth microdilution processes, essential oil and fluconazole were diluted in RPMI 1640, and 100µL of each diluted solution was added to the 96-well microtiter plate. As well as the standard fungal suspensions were diluted 1:1000 in RPMI 1640 medium and added to each well. All microplates were incubated at 37°C for 24-48h. Growth inhibition was determined after the incubation period and compared with positive control.

Statistical analysis

Data were entered into Excel 2016 and were analyzed in SPSS 16 software and descriptive rioncstatistics, and Wilcoxon test was calculated. Also, the data distribution was checked using Shapiro-Wilk and Kolmogorov-Smirnov tests, and the data distribution was not normal in any of the groups, and due to non-normality, non-parametric tests were used for data analysis.

Findings

Chemical component

The constituents of the essential oil of *S. macrosiphon* are presented in Table 1. Overall, 29 components were identified in the leaf essential oil. The main constituents of the oil were Butyl benzoate (49.16%), n-Hexyl benzoate (7%), Isospathulenol (4.8%), Cyperene (4.1%), Benzoic acid, 2-methyl-, butyl ester (3.88%), beta-caryophyllene (3.54%), and β-Elemene (3.02%).

Table 1. Chemical component of *Salvia macrosiphon*

| PK Name | RT (min) | Standard Ritation Index | Conc. |
|---|----------|-------------------------|-------|
| 1 Methyl benzoate | 17.707 | 1091 | 0.27 |
| 2 linalool | 17.844 | 1098 | 3.31 |
| 3 Hexyl isobutyrate | 19.461 | 1150 | 0.82 |
| 4 Ethyl benzoate | 20.496 | 1170 | 0.31 |
| 5 Hexyl 2-methylbutanoate | 22.690 | 1234 | 0.65 |
| 6 Hexyl 3-methylbutanoate | 22.896 | 1243 | 0.34 |
| 7 Propyl Benzoate | 24.09 | 1247 | 0.77 |
| 8 Butyl benzoate | 26.416 | 1339 | 49.16 |
| 9 Octyl isobutyrate | 27.669 | 1348 | 0.98 |
| 10 β-Elemene | 28.286 | 1375 | 3.02 |
| 11 Cyperene | 29.240 | 1398 | 4.10 |
| 12 Benzoic acid, 2-methyl-, butyl ester | 29.440 | 1409 | 3.88 |
| 13 beta-caryophyllene | 29.777 | 1418 | 3.54 |
| 14 (+)-Aromadendrene | 30.555 | 1439 | 0.39 |
| 15 alpha-Humulene | 31.166 | 1443 | 1.34 |
| 16 (E)-germacrene D | 31.338 | 1480 | 1.62 |
| 17 Bicyclogermacrene | 31.441 | 1494 | 0.71 |
| 18 δ-Selinene | 31.784 | 1495 | 2.86 |
| 19 n-Hexyl benzoate | 32.955 | 1576 | 7 |
| 20 Caryophyllene oxide | 34.321 | 1581 | 1.19 |
| 21 Salvial-4(14)-en-1-one | 34.504 | 1589 | 0.77 |
| 22 Ledene | 35.556 | 1600 | 0.41 |
| 23 Caryophyllenol II | 35.721 | 1614 | 0.93 |
| 24 Isospathulenol | 36.379 | 1623 | 4.83 |
| 25 Isoaromadendrene epoxide | 37.024 | 1682 | 2.29 |
| 26 Heptadecane | 39.191 | 1700 | 0.45 |
| 27 Benzyl benzoate | 39.545 | 1762 | 0.68 |
| 28 Octyl benzoate | 39.905 | 1766 | 2.75 |
| 29 Palmitic acid | 44.186 | 1984 | 0.63 |

Antifungal activities

As shown in Table 2, the MIC value showed that *S. macrosiphon* has a better effect against different *Candida* species. Besides, the MIC value range was lower in non-albicans species (0.039-0.15µl/ml) than *C.albicans* (0.039-2.5µl/ml). Based on MIC₉₀ fluconazole had poor activity against *C.glabrata* isolates (7.6µg/ml). However, a comparison of MIC_{GM} between *S. macrosiphon* and fluconazole revealed that only *C.parapsilosis* had this value lower in fluconazole (0.088µg/ml). Statistical analysis showed that there was a significant difference between the mean of fluconazole and essential oil in total *Candida* isolates (p=0.001, p<0.05).

Table 2. Minimum inhibitory concentration range, MIC₅₀, MIC₉₀, and MIC_{GeoMean} (MIC_{GM}) of *S. macrosiphon* compared with fluconazole against *Candida* species

| Organisms | <i>S. macrosiphon</i> (µl/ml) | | | | Fluconazole (µg/ml) | | | |
|---------------------------------------|-------------------------------|-------------------|-------------------|-------------------|---------------------|-------------------|-------------------|-------------------|
| | MIC range | MIC ₅₀ | MIC ₉₀ | MIC _{GM} | MIC range | MIC ₅₀ | MIC ₉₀ | MIC _{GM} |
| <i>Candida albicans</i> (n=56) | 0.039-2.5 | 0.078 | 0.46 | 0.44 | 0.0625-4 | 1 | 2 | 0.7 |
| <i>Candida parapsilosis</i> (n=12) | 0.039-0.15 | 0.078 | 0.141 | 0.1 | 0.0312-0.5 | 0.18 | 0.5 | 0.088 |
| <i>Candida glabrata</i> (n=12) | 0.039-0.15 | 0.078 | 0.078 | 0.056 | 0.0625-32 | 0.5 | 7.6 | 0.7 |

A comparison of mean and standard deviation showed that *Candida* isolates in *S. macrosiphon* essential oil were lower than fluconazole (Table 2). As shown, the difference in antifungal activity between *S. macrosiphon* essential oil and fluconazole was significant in all *Candida* species (p<0.05).

Table 3. Mean, standard deviation and p-value of different *Candida* species in two essential oil and fluconazole groups

| Microorganism | Mean±Standard Deviation | | p-value* |
|------------------------|-------------------------|-------------|----------|
| | <i>S. macrosiphon</i> | Fluconazole | |
| <i>C. albicans</i> | 0.281±0.583 | 1.489±4.234 | 0.0001 |
| <i>C. parapsilosis</i> | 0.0867±0.0315 | 0.242±0.168 | 0.003 |
| <i>C. glabrata</i> | 0.677±0.0323 | 4.234±9.077 | 0.002 |

* Wilcoxon test

Discussion

Candidiasis is the most opportunistic infection and its treatment has always been a challenge [13]. The drug resistance of *Candida* isolates which are sometimes intrinsic and mostly acquired, has made it difficult to treat patients [14]. Therefore, choosing a suitable drug with the lowest cost and no recurrence of infection has always been desired. Herbal medicines with low side effects and availability have long been of interest [15]. In this study, the essential oil of *S. macrosiphon* was analyzed by the GC-MS method, and its constituent elements were determined. The most compounds in this essential oil are butyl benzoate (49.16%), n-hexyl benzoate (7%), isopatenolol (4.83%), cuprene (4.10%), benzoic acid 2-methyl-1-butyl ester (3.88%), linalool (3.31%), beta caryophyllene (3.54%), and beta elemen (3.02%). Various studies investigated the main compounds found in different species of *Salvia*. For example, in the study, Sajadi et al. proved the presence of at least forty-six compounds in the essential oil of *S. macrosiphon*. Among these compounds, beta-pinene (15.3%), germacrene-di (10.1%), spatholenol (7.7%), and 1 and 8-cineole (7.4%) were the main compounds in the essential oil of *S. macrosiphon* [16]. Also, in the study conducted by Taari et al., the most important components of the essential oil of this plant, 9- and 8-cineole, alpha-thujone, viridiflurol, and beta-thujone were introduced [17]. This is even though the above compounds were not detected in the present study. The difference in the composition of *Salvia* species essential oil can be attributed to reasons such as ecological differences. The compounds in the essential oils of plants are caused by ecological differences such as latitude and longitude, altitude, temperature, humidity, climate and soil, metabolic pathways, and biosynthesis of effective substances in these plants, which result in various secondary metabolites being biosynthesized under different environmental conditions. Various studies have confirmed this. Also, in similar weather conditions, secondary compounds in different plants have similarities. Of course, the conditions and types of studies are different, which can affect the results.

The present study was done to test the antifungal activity of *S. macrosiphon* based on the microdilution method. In the literature, the antimicrobial activity of some genera of *Salvia* essential oils against microbes has been reported [9, 18]. However, the use of broth microdilution method in the effect of antifungal activity of *S. macrosiphon* has been done for the first time in Iran in the present

study. The results of the present study showed that the essential oil of *S. macrosiphon* had great activity against *Candida* isolates. So, the essential oil of *S. macrosiphon* affected the growth of *C. albicans* and the MIC₅₀ of this plant was equal to 0.78 µl/ml. whereas, the MIC₅₀ value was 1 µg/ml for fluconazole against *C. albicans* isolates. Agree with results of the present study, the study conducted by Atai et al. reported MIC=1 µg for *Salvia* species against *C. albicans* [19]. Also, in the study of Banaeian-Boroujeni et al., *S. officinalis* with a concentration of 1.25 µg/ml was able to inhibit the standard strain of *C. albicans* [20]. However, in the study of Sookto et al., the effect of the extract and oil of several plants from the Lamiaceae family, including *S. officinalis* and Chamomile, on *C. albicans* was investigated. *S. officinalis* essential oil with a concentration of 78.2 mg/l inhibited the growth of *C. albicans* [21]. Pozzatti et al reported that the essential oil of *S. officinalis* had no effect against fluconazole resistance and susceptible *C. albicans* [22]. This difference between our results and Pozzatti et al, may be due to the different species of *Salvia* tested. Besides, the present study revealed that *S. officinalis* essential oil had an inhibition effect against *C. glabrata* isolates (MIC_{GM}=0.056 µL/ml). This antifungal activity has a better inhibitory effect compared to fluconazole (MIC_{GM}=0.7 µg/ml) against *C. glabrata* isolates. However, Salari et al, reported the methanolic extract of *S. rhytidea* had anti-fungal activity against *C. glabrata* isolates (MIC₅₀=100 µg/ml) [23]. Resistance to fluconazole has been reported during the treatment of different forms of candidiasis [24, 25]. There is no study similar to the present study for the effect of the *S. macrosiphon* on *Candida* isolates and its comparison with fluconazole. However, results of the present study indicated that the MIC₅₀ value of *S. macrosiphon* was lower than that of fluconazole against *Candida* isolates.

The mechanism of the inhibitory effect of *S. macrosiphon* is not clear. But in one study it was mentioned that probably due to the destruction of the cell wall by lipophilic compounds in this mechanism. Significant leakage of cell material indicates irreversible cell membrane damage [26]. On the other hand, the difference in the concentration of *Salvia* species in inhibiting the growth of *Candida*, which is observed in the results of various research, can be due to geophysical factors and different species of this plant, or the methods of essential oil extraction, oil preparation, and laboratory methods [23, 27, 28].

Generally, one of the limitations of this study is the limited effect of essential oil on clinical isolates in vitro examination and the lack of simultaneous comparison in vivo conditions.

Based on the results of this study, it can be hoped that recurrent candidal infections will be treated in the future with different formulations of *S. macrosiphon* along with antifungal drugs. However, confirmation of the present results in similar studies is necessary.

Conclusion

Salvia macrosiphon has great anticandida activity than fluconazole. Therefore, it can be hoped that it can be used as an antifungal compound in the treatment of *Candida* infections in the future. However, obtaining definitive results requires specialized laboratory studies and identification of the effective components of plants and clinical studies. Therefore, in future studies, this issue can also be investigated in the patient with candidiasis.

Acknowledgments: We are grateful to Yasuj University of Medical Sciences, Yasuj, Iran for supporting this study.

Ethical Permissions: This study was approved with the ethical approval code of IR.YUMS.REC.1400.017.

Conflicts of Interests: The authors declare that there is no conflict of interest.

Authors' Contribution: Nouripour-Sisakht S (First author), Methodologist/Discussion author (25%); Diba A (Second author), Introduction author (10%); Razmjoue D (Third author), Original researcher (10%); Sadeghi Mansourkhani H (Fourth author), Introduction author (10%); Zanganeh P (Fift author), Original researcher (10%); Salah M (Sixt author), Introduction author (5%); Gharaghani M (Eighth author), Assistant/Discussion author (25%).

Funding/Support: This work was financially supported by Yasuj University of Medical Sciences, Iran (grant No. 990241).

References

- 1- Gharaghani M, Taghipour S, Halvaezadeh M, Mahmoudabadi AZ. Candiduria; a review article with specific data from Iran. *Turkish J Urol.* 2018;44(6):445.
- 2- Ciurea CN, Kosovski I-B, Mare AD, Toma F, Pintea-Simon IA, Man A. *Candida* and candidiasis-opportunism versus pathogenicity: A review of the virulence traits. *Microorganisms.* 2020;8(6):857.

- 3- Vila T, Sultan AS, Montelongo-Jauregui D, Jabra-Rizk MA. Oral candidiasis: a disease of opportunity. *J Fungi*. 2020;6(1):15.
- 4- Ordaya EE, Clement J, Vergidis P. The role of novel antifungals in the management of Candidiasis: A clinical perspective. *Mycopathologia*. 2023;188(6):937-48.
- 5- Houšť J, Spížek J, Havlíček V. Antifungal drugs. *Metabolites*. 2020;10(3):106.
- 6- Berkow EL, Lockhart SR. Fluconazole resistance in *Candida* species: A current perspective. *Infection Drug Resist*. 2017;10:237-45.
- 7- Maliki I, Moussaoui AE, Ramdani M, ELBadaoui K. Phytochemical screening and the antioxidant, antibacterial and antifungal activities of aqueous extracts from the leaves of *Salvia officinalis* planted in Morocco. *Moroccan J Chem*. 2021;9(2):354-68.
- 8- Farhadi F, Sahebkar A, Eghbali S. Chemical composition and biological activity of the essential oils of three *Salvia* species from South Khorasan: *Salvia macrosiphon* Boiss., *Salvia spinosa* L., and *Salvia sharifii* Rech. f. & Esfand. *J Essent Oil Bearing Plant*. 2023;26(3):695-704.
- 9- Balaie-Kahnamoei M, Eftekhari M, Ardekani MRS, Akbarzadeh T, Saeedi M, Jamalifar H, et al. Phytochemical constituents and biological activities of *Salvia macrosiphon* Boiss. *BMC Chem*. 2021;15(1):4.
- 10- Banan ZM, Yaghobfar A, Mojab F. The chemical composition of *salvia macrosiphon* seed. The chemical composition of *salvia macrosiphon* seed. *Iran J Pharmaceutical Sci*. 2023;19(2):166-75.
- 11- Ashley ED. Antifungal drugs: special problems treating central nervous system infections. *J Fungi*. 2019;5(4):97.
- 12- Altınbaş R, Barış A, Şen S, Öztürk R, Kiraz N. Comparison of the Sensititre YeastOne antifungal method with the CLSI M27-A3 reference method to determine the activity of antifungal agents against clinical isolates of *Candida* spp. *Turk J Med Sci*. 2020;50(8):2024-31.
- 13- Neal CM, Martens MG. Clinical challenges in diagnosis and treatment of recurrent vulvovaginal candidiasis. *SAGE Open Med*. 2022;10:20503121221115201.
- 14- Lee Y, Puumala E, Robbins N, Cowen LE. Antifungal drug resistance: molecular mechanisms in *Candida albicans* and beyond. *Chem Rev*. 2020;121(6):3390-411.
- 15- Subramaniyan V, Kayarohanam S, Kumar JA, Kumarasamy V. Impact of herbal drugs and its clinical application. *Int J Res Pharmaceutical Sci*. 2019;10(2):1340-5.
- 16- Sajadi S, Emami Sa, Nemati R. Composition of the essential oil of *salvia macrosiphon* boiss. *Pharmaceutical Sci*. 2000;(3):51-6. [Persian]
- 17- Taarit MB, Msaada K, Hosni K, Hammami M, Kchouk ME, Marzouk B. Plant growth, essential oil yield and composition of sage (*Salvia officinalis* L.) fruits cultivated under salt stress conditions. *Industrial Crops Prod*. 2009;30(3):333-7.
- 18- Adam K, Sivropoulou A, Kokkini S, Lanaras T, Arsenakis M. Antifungal activities of *Origanum vulgare* subsp. *hirtum*, *Mentha spicata*, *Lavandula angustifolia*, and *Salvia fruticosa* essential oils against human pathogenic fungi. *J Agric Food Chem*. 1998;46(5):1739-45.
- 19- Atai Z, Ansari M, Mousavi A, Mirzaei A. In-vitro study of antifungal effects of selected herbal extracts on standard and wild strains of *Candida albicans*. *J Iran Dental Assoc*. 2007;19(2):91-7.
- 20- Banaeian Bs, Mobini G, Rafeian Km, Rasti Bm, Sereshti M, Validi M. A comparative study of the effects of Clotrimazole and *Salvia officinalis* extract against vaginal *Candida albicans* isolated from women with candidacies vaginitis. *Yafte*. 2015;17(1):95-103. [Persian]
- 21- Sookto T, Srithava J T, Thaweboon S, Thaweboon B, Shrestha B. In vitro effects of *Salvia officinalis* L. essential oil on *Candida albicans*. *Asian Pac J Tropical Biomed*. 2013;3(5):376-80.
- 22- Pozzatti P, Scheid LA, Spader TB, Atayde ML, Santurio JM, Alves SH. In vitro activity of essential oils extracted from plants used as spices against fluconazole-resistant and fluconazole-susceptible *Candida* spp. *Can J Microbiol*. 2008;54(11):950-6.
- 23- Salari S, Bakhshi T, Sharififar F, Naseri A, Almani PGN. Evaluation of antifungal activity of standardized extract of *Salvia rhytidea* Benth. (Lamiaceae) against various *Candida* isolates. *J Mycologie Med*. 2016;26(4):323-30.
- 24- Lee I, Fishman NO, Zaoutis TE, Morales KH, Weiner MG, Synnestvedt M, et al. Risk factors for fluconazole-resistant *Candida glabrata* bloodstream infections. *Arch Intern Med*. 2009;169(4):379-83.
- 25- Won EJ, Choi MJ, Kim M-N, Yong D, Lee WG, Uh Y, et al. Fluconazole-resistant *Candida glabrata* bloodstream isolates, South Korea, 2008-2018. *Emerg Infect Dis*. 2021;27(3):779.
- 26- Zhumaliyeva G, Zhussupova A, Zhusupova GE, Błońska-Sikora E, Cerreto A, Omirbekova N, et al. Natural compounds of *salvia* l. genus and molecular mechanism of their biological activity. *Biomedicines*. 2023;11(12):3151.
- 27- Sen Utsukarci B, Gürdal Abamor M, Bilgin M, Şatana D, Demirci B, Tan N, et al. Biological activities of various extracts from *Salvia cassia* Sam. ex Rech. f. and chemical composition of its most active extract. *Rec Nat Prod*. 2019;13(1)24-36.
- 28- Potente G, Bonvicini F, Gentilomi GA, Antognoni F. Anti-*Candida* activity of essential oils from Lamiaceae plants from the Mediterranean area and the Middle East. *Antibiotics*. 2020;9(7):395.